Clinical Trials Directory

Trials / Unknown

UnknownNCT04898361

PFO Occlusion and Atrial Fibrillation

Electrophysiological and Echocardiographic PREDICTors of Atrial Fibrillation Following Interventional Closure of Patent Foramen Ovale in Cryptogenic Stroke: PREDICT-AF-PFO

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
University Hospital, Saarland · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Interventional closure of patent foramen ovale (PFO) associates with reduced risk of stroke recurrence in patients with cryptogenic ischemic stroke as reported in the recent CLOSE and REDUCE trials. The long-term follow-up results of the RESPECT and DEFENSE-PFO trial confirmed these findings. PFO closure is therefore recommended in patient with cryptogenic ischemic stroke and PFO according to the current German interdisciplinary guidelines. It is likely that the number of PFO closure procedures will increase significantly in the near future. However, new onset atrial fibrillation (AF) appears to increase in patients following this procedure. In the REDUCE study, new onset atrial fibrillation was detected in 6.6% patients in the PFO closure group compared with 0.4% in the control group (medical treatment); 59% of these patients were diagnosed within the first two weeks following the procedure and 83% within 45 days, respectively. These results were consistent with the CLOSE study: AF was detected in 4.6% patients in the intervention group vs. 0.9% in the control group. Up until today, markers to identify and quantify the individual risk of AF onset are lacking. Furthermore, under-reporting and under-detection of AF occurrence after PFO closure is likely. This study is designed to to assess the prevalence and and identification of electrophysiological and echocardiographic parameters of new-onset AF.

Conditions

Interventions

TypeNameDescription
PROCEDUREPFO closureInterventional closure of a patent foramen oval preceded by an electrophysiological study

Timeline

Start date
2020-01-15
Primary completion
2021-06-01
Completion
2022-06-01
First posted
2021-05-24
Last updated
2021-05-24

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT04898361. Inclusion in this directory is not an endorsement.